Mirum Pharmaceuticals (MIRM) Cash from Financing Activities (2019 - 2026)

Mirum Pharmaceuticals' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $270.1 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 4147.19% year-over-year to $270.1 million in Q1 2026; TTM through Mar 2026 was $303.9 million, a 1229.64% increase from a year earlier, with the FY2025 full-year figure at $40.1 million, up 126.8% from the prior year.
• Cash from Financing Activities advanced to $270.1 million in Q1 2026 per MIRM's latest filing, from $9.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $270.1 million in Q1 2026 and bottomed at -$329000.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $8.7 million (2025), against an average of $45.5 million.
• Biggest YoY gain for Cash from Financing Activities was 24846.67% in 2022; the steepest drop was 153.5% in 2022.
• Year by year, Cash from Financing Activities stood at -$329000.0 in 2022, then soared by 640.12% to $1.8 million in 2023, then jumped by 200.51% to $5.3 million in 2024, then surged by 68.52% to $9.0 million in 2025, then surged by 2901.21% to $270.1 million in 2026.
• Per Business Quant, the three latest MIRM Cash from Financing Activities figures stand at $270.1 million (Q1 2026), $9.0 million (Q4 2025), and $16.1 million (Q3 2025).